Company profile
Foghorn Therapeutics Inc.
NASDAQ:FHTXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Camibirstat | phase1 | — | 2 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04891757 | phase1 | active_not_recruiting | 2021-06-14 | 2025-09-01 | Foghorn Therapeutics Inc. | FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies |
| NCT04879017 | phase1 | terminated | 2021-05-11 | 2023-11-30 | Foghorn Therapeutics Inc. | FHD-286 in Subjects With Metastatic Uveal Melanoma |
| NCT04965753 | phase1 | terminated | 2021-08-17 | 2023-12-04 | Foghorn Therapeutics Inc. | FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors |
FDA applications (0)
No records yet.